India's Gennova working on Omicron-specific COVID-19 vaccine — source | Inquirer News
Close  

India’s Gennova working on Omicron-specific COVID-19 vaccine — source

/ 03:16 PM January 17, 2022
FILE PHOTO: 3D-printed small toy figurines, a syringe and vial labelled "coronavirus disease (COVID-19) vaccine" are seen in front of India flag in this illustration taken May 4, 2021. REUTERS/Dado Ruvic/Illustration/File Photo

FILE PHOTO: 3D-printed small toy figurines, a syringe and vial labelled “coronavirus disease (COVID-19) vaccine” are seen in front of India flag in this illustration taken May 4, 2021. REUTERS/Dado Ruvic/Illustration/File Photo

NEW DELHI — India’s Gennova Biopharmaceuticals is working on an Omicron-specific COVID-19 vaccine candidate that could be ready in a month or two, a person with direct knowledge of the matter told Reuters.

The source, who did not want to be named as the information was private, said the product might need a small trial in India before it could be rolled out as a booster or standalone vaccine.

ADVERTISEMENT

A representative for Gennova, a unit of drugmaker Emcure Pharmaceuticals that does business in some 70 countries, did not immediately respond to a request for comment.

Pfizer Inc said last week a redesigned COVID-19 vaccine that specifically targets the Omicron coronavirus variant could be ready to launch by March.

FEATURED STORIES

The source said Gennova on Friday separately submitted to India’s drug regulator phase 2 trial data for its original mRNA vaccine candidate. The government said last year that product was found to be “safe, tolerable, and immunogenic” in the participants of an initial study.

If given emergency-use approval, this would be the country’s first mRNA COVID-19 vaccine like the ones developed by Pfizer and Moderna.

Subscribe to our daily newsletter

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.
Read Next
Don't miss out on the latest news and information.

Subscribe to INQUIRER PLUS to get access to The Philippine Daily Inquirer & other 70+ titles, share up to 5 gadgets, listen to the news, download as early as 4am & share articles on social media. Call 896 6000.

TAGS: COVID-19 surge, Gennova Biopharmaceuticals, India, mRNA vaccines, Omicron variant
For feedback, complaints, or inquiries, contact us.

Subscribe to our daily newsletter

By providing an email address. I agree to the Terms of Use and
acknowledge that I have read the Privacy Policy.



© Copyright 1997-2022 INQUIRER.net | All Rights Reserved

We use cookies to ensure you get the best experience on our website. By continuing, you are agreeing to our use of cookies. To find out more, please click this link.